<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05795829</url>
  </required_header>
  <id_info>
    <org_study_id>LPCTP-2021-004</org_study_id>
    <nct_id>NCT05795829</nct_id>
  </id_info>
  <brief_title>Ultrasound Ablation for Essential Hypertension（FIM）</brief_title>
  <official_title>First in Man Study to Evaluate the Safety and Efficacy of Disposable Intravascular Ultrasound Ablation Catheters and Ultrasound Ablation Instrument in the Treatment of Essential Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lepu Medical Technology (Beijing) Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lepu Medical Technology (Beijing) Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and feasibility of disposable intravascular ultrasound ablation&#xD;
      catheter and ultrasound ablation instrument in the treatment of essential hypertension.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Feasibility Research This is a prospective, small-sample, single-group study. A total of 10&#xD;
      subjects are planned to be included in this study. Disposable intravascular catheter and&#xD;
      instrument are used for intravascular ultrasound ablation. All participants will be followed&#xD;
      up by telephone or outpatient at 1, 2 and 6 months post-procedure, with procedural success&#xD;
      rate as the primary endpoint. At the same time, the incidence of adverse events will be&#xD;
      observed to make a preliminary evaluation of the safety and feasibility of disposable&#xD;
      intravascular catheter and instrument, and to provide data support for the second-stage&#xD;
      confirmatory study.&#xD;
&#xD;
      In feasibility research, statistical analysis of data will be performed after 30 days&#xD;
      postoperative follow-up of the subjects, and the safety and feasibility of disposable&#xD;
      intravascular catheter and instrument will be preliminarily evaluated before entering the&#xD;
      stage of confirmatory trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 16, 2023</start_date>
  <completion_date type="Anticipated">February 29, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Procedural success</measure>
    <time_frame>Before discharge (post-procedure), up to 7 days</time_frame>
    <description>Procedural success was defined as the absence of renal arterial related complication during the subject's hospitalization based on the device success.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in average 24-hour/night-time ambulatory Systolic Blood Pressure (SBP)</measure>
    <time_frame>1 month, 2months, 6 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in average 24-hour/daytime/night-time ambulatory Diastolic Blood Pressure (DBP)</measure>
    <time_frame>1 month, 2months, 6 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in average daytime ambulatory Systolic Blood Pressure (SBP)</measure>
    <time_frame>1 month, 2months, 6 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in office systolic blood pressure</measure>
    <time_frame>1 month, 2 months, 6 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in office diastolic blood pressure</measure>
    <time_frame>1 month, 2 months, 6 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device success</measure>
    <time_frame>immediate post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of achieving target office systolic blood pressure</measure>
    <time_frame>1 month, 2 months, 6 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Significant embolic events resulting in end-organ damage</measure>
    <time_frame>1 month, 2 months, 6 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute myocardial infarction, stroke, transient ischemic attack, cerebrovascular accident</measure>
    <time_frame>1 month, 2 months, 6 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>End-stage renal disease</measure>
    <time_frame>1 month, 2 months, 6 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal artery or vascular complications requiring intervention</measure>
    <time_frame>1 month, 2 months, 6 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Significant (50%) and severe (75%) new onset renal stenosis</measure>
    <time_frame>6 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe access site complications</measure>
    <time_frame>1 month, 2 months, 6 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>1 month, 2 months, 6 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stability of ultrasonic ablation instrument</measure>
    <time_frame>immediate post-procedure</time_frame>
    <description>Whether the instrument has failed during the use of the device, and whether the fault can be recovered.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interface friendliness of ultrasonic ablation instrument</measure>
    <time_frame>immediate post-procedure</time_frame>
    <description>It is defined as whether the operation interface and difficulty of operation of the instrument are convenient.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Uncontrolled Essential Hypertension</condition>
  <arm_group>
    <arm_group_label>Disposable Intravascular Ultrasound Ablation Catheter and Ultrasound Ablation Instrument</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will receive treatment from the disposable intravascular ultrasound ablation catheter.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>disposable intravascular ultrasound ablation catheter and ultrasound ablation instrument</intervention_name>
    <description>Disposable intravascular ultrasound ablation catheters (used with an ultrasound ablation instrument) can use ultrasound energy to block sympathetic activity in the renal arteries.</description>
    <arm_group_label>Disposable Intravascular Ultrasound Ablation Catheter and Ultrasound Ablation Instrument</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age≥18 and≤80 years old, no gender limitation;&#xD;
&#xD;
          2. Two or more antihypertensive drugs should be statically taken for at least 4 weeks&#xD;
             before randomization and the prescribed dose should be ≥ 50% of the manufacturer's&#xD;
             maximum dose， angiotensin-converting enzyme inhibitor (ACEI) (or angiotensin-Ⅱ&#xD;
             receptor antagonist (ARB)) and calcium channel blocker (CCB) (or thiazide diuretic)&#xD;
             are required to be used in combination. Blood pressure meets the following conditions:&#xD;
             1) office systolic blood pressure (SBP)≥150mmHg and&lt;180mmHg; 2) office diastolic blood&#xD;
             pressure (DBP) ≥90mmHg;&#xD;
&#xD;
          3. 24-hour ambulatory systolic blood pressure: ≥135 mmHg and &lt;170 mmHg;&#xD;
&#xD;
          4. A recorded history of essential hypertension;&#xD;
&#xD;
          5. Understands the purpose of this study, and is willing to sign the Informed Consent and&#xD;
             complete clinical follow-up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Ineligible renal artery anatomy including : (1) multiple renal arteries, (2) main&#xD;
             renal artery diameter &lt;4mm or length &lt;20mm, (3) renal artery stenosis &gt; 50% in the&#xD;
             main renal artery, (4) atherosclerosis of the renal artery, renal artery aneurysm,&#xD;
             fibromuscular dysplasia or calcification, (5) pre-existing renal stent, (6) single&#xD;
             kidney&#xD;
&#xD;
          2. Estimated glomerular filtration rate (eGFR) &lt;45 mL/min/1.73 m2&#xD;
&#xD;
          3. Type Ⅰ diabetes mellitus or poorly controlled type Ⅱ diabetes mellitus (defined as&#xD;
             plasma Hb1Ac≥ 9.0% or 24-hour urinary protein quantification &gt;1g/24h or proliferative&#xD;
             retinopathy)&#xD;
&#xD;
          4. Postural hypotension&#xD;
&#xD;
          5. Recent vascular events: Experienced acute myocardial infarction, unstable angina,&#xD;
             syncope, or cerebrovascular accident within 3 months of the screening period&#xD;
&#xD;
          6. Possible secondary hypertension&#xD;
&#xD;
          7. Respiratory support: The individual requires long-term oxygen support or mechanical&#xD;
             ventilation other than nocturnal respiratory support for sleep apnea&#xD;
&#xD;
          8. Life expectancy &lt;1 year&#xD;
&#xD;
          9. Female who is pregnant, nursing, or planning to become pregnant&#xD;
&#xD;
         10. Subjects who are currently enrolled in another clinical trial and have not completed&#xD;
             their primary endpoint&#xD;
&#xD;
         11. Subjects who are allergic to contrast medium&#xD;
&#xD;
         12. Subjects who are unsuitable for the trial ，because of poor patient compliance or other&#xD;
             reasons judged by the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bo Yu</last_name>
    <role>Study Chair</role>
    <affiliation>The Second Affiliated Hospital of Harbin Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jing Huang</last_name>
    <role>Study Chair</role>
    <affiliation>The Second Affiuated Hospital of Chongqing Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ting Zhang</last_name>
    <phone>010-80120666</phone>
    <email>ting_zhang@lepumedical.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Second Affiuated Hospital of Chongqing Medical University</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jing huang</last_name>
      <phone>023-63693083</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Harbin Medical University</name>
      <address>
        <city>Harbin</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bo Yu</last_name>
      <phone>0451-86605180</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>March 8, 2023</study_first_submitted>
  <study_first_submitted_qc>March 21, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2023</study_first_posted>
  <last_update_submitted>March 21, 2023</last_update_submitted>
  <last_update_submitted_qc>March 21, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ultrasound Ablation Catheter</keyword>
  <keyword>Renal Sympathetic Denervation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Essential Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

